Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf

Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice

Klaus Okkenhaug, Antonio Bilancio, Géraldine Farjot et al. · Science · 2002 · 937 citations

Life Sciences, Immunology, Molecular Biology +17

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data

Kaoxiang Sun · Chinese New Drugs Journal · 2005 · 764 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah Meadows, Sarah E. M. Herman et al. · Blood · 2010 · 718 citations · Full text

Medicine, Oncology, Pharmacology +11

The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data

R. Scott Obach, James G. Baxter, Theodore E. Liston et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 591 citations

Pharmacy, Pharmacokinetics, Pharmacology +14